Craft
AC Immune

AC Immune

Market Capitalization

$174.4 M

2022-09-21

AC Immune Summary

Company summary

Overview
AC Immune is a biopharmaceutical company developing therapeutics against Alzheimer´s disease and other conformational diseases. Its technology platforms allow to discover, design, and develop antibodies, small molecules, and vaccines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.
Type
Public
Founded
2003
HQ
Lausanne, CH | view all locations
Website
https://www.acimmune.com
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Douglas E. Williams

    Douglas E. Williams, Chairman

    • Andrea Pfeifer

      Andrea Pfeifer, Co-Founder, Chief Executive Officer and Director

    • Jean-Fabien Monin
    • Jörg Hornstein

      Jörg Hornstein, Chief Financial Officer

      LocationsView all

      1 location detected

      • Lausanne, VD HQ

        Switzerland

        Route Cantonale

      AC Immune Financials

      Summary financials

      Gross profit (FY, 2021)
      CHF1.2M
      Net income (FY, 2021)
      (CHF73.0M)
      Cash (FY, 2021)
      CHF82.2M
      EBIT (FY, 2021)
      (CHF79.0M)
      Enterprise value
      $95.1M

      Footer menu